MILLENNIUM
Peptides for Health

MOTS-c:
Clinical Overview for Metabolic and Cellular Optimization

Mark L. Gordon, MD

MOTS-c: Clinical Overview for Metabolic and Cellular Optimization.

Mark L. Gordon, MD (2025.08)

Overview

MOTS-c (Mitochondrial ORF of the Twelve S-c) is a 16-amino acid mitochondrial-derived peptide (MDP) encoded within the 12S rRNA region of the mitochondrial genome. Unlike most peptides which are nuclear-encoded, MOTS-c is transcribed and translated from the mitochondria, making it a unique peptide hormone that bridges mitochondrial function with systemic metabolic regulation. It functions as a key regulator of cellular homeostasis and stress resilience by targeting nuclear gene expression and metabolic signaling pathways.

MOTS-c plays a central role in energy balance, **insulin sensitivity**, mitochondrial biogenesis, and cellular protection against oxidative and inflammatory stress. It is increasingly recognized as a critical signaling molecule in age-related disorders, including metabolic syndrome, **type 2 diabetes**, obesity, sarcopenia, and neurodegeneration. Studies in both animal models and humans have demonstrated its ability to enhance physical performance, reverse diet-induced obesity, improve insulin resistance, and extend healthspan.

What distinguishes MOTS-c from other metabolic peptides is its ability to translocate to the nucleus during cellular stress, where it activates adaptive gene networks related to antioxidant defense, metabolism, and longevity pathways. This mitochondrial-to-nuclear signaling defines MOTS-c as a mitokine—a mitochondria-derived hormone with endocrine-like effects. Its broad pleiotropic effects have positioned MOTS-c as a promising candidate for therapeutic use in metabolic, neurodegenerative, and age-related diseases.

Mechanism of Action

MOTS-c exerts its biological effects through a unique cross-talk between the mitochondria and the nucleus, a form of retrograde signaling rarely seen with other endogenous peptides. Under conditions of metabolic stress, MOTS-c is upregulated and translocates from the mitochondria to the nucleus, where it binds chromatin and modulates gene expression related to cellular metabolism, inflammation, and stress response.

At the molecular level, MOTS-c primarily acts via activation of the **AMP-activated protein kinase (AMPK)** pathway, a central regulator of energy homeostasis. AMPK activation leads to enhanced fatty acid oxidation, **improved glucose uptake**, inhibition of lipogenesis, and increased mitochondrial biogenesis. This pathway also plays a critical role in **autophagy** and mitochondrial quality control.

MOTS-c also inhibits the **folate-methionine cycle** and downstream de novo purine biosynthesis, thereby mimicking a nutrient-deficient state and inducing a hormetic adaptive response¥. This mechanism increases stress resistance, reduces oxidative damage, and promotes longevity-associated gene expression such as **PGC-1α**, **FOXO**, and **SIRT1**.

Additional mechanisms include:

- **Reduction of pro-inflammatory cytokines** such as TNF-α and IL-6.
- **Improved insulin signaling** through IRS-1 and GLUT4 translocation.
- **Suppression of mTOR**, mimicking caloric restriction and promoting autophagy.
- **Mitochondrial protection** via enhanced mitophagy and decreased mitochondrial ROS.

MOTS-c's pleiotropic mechanisms position it as a metabolic sentinel capable of coordinating adaptive stress responses at both the cellular and systemic level—spanning glucose and lipid metabolism, immune function, cardiovascular protection, and neuroprotection.

¥Hormetic refers to a biological phenomenon where low doses of potentially harmful stressors can produce beneficial effects, while higher doses may be toxic or harmful. This concept suggests that small amounts of stress can enhance resilience and promote health.

Clinical Applications and Benefits

1. Metabolic Health and Insulin Sensitivity

MOTS-c plays a critical role in correcting metabolic dysfunctions, particularly those associated with insulin resistance and type 2 diabetes. It improves glucose uptake in skeletal muscle independently of insulin by activating the AMPK pathway and enhancing GLUT4 translocation. In both animal and human models, MOTS-c administration results in reductions in fasting glucose, improved glucose tolerance, enhanced insulin sensitivity, and normalization of HbA1c. Additionally, it decreases adiposity, hepatic fat accumulation, and serum triglycerides—making it a candidate for treating metabolic syndrome and non-alcoholic fatty liver disease (NAFLD).

2. Mitochondrial Biogenesis and Exercise Mimetic Effects

As a mitochondrial-derived peptide, MOTS-c functions as an exercise mimetic. It enhances mitochondrial biogenesis via PGC-1α and SIRT1 activation, supporting endurance, strength, and metabolic flexibility. In murine models, MOTS-c increased running time, reduced lactate production, and protected against high-fat diet-induced obesity. It is under investigation as a novel agent to combat age-related sarcopenia and mitochondrial decline.



3. Aging and Longevity Promotion

MOTS-c mimics caloric restriction by suppressing the folate cycle and mTOR signaling, two nutrient-sensing pathways linked to aging. It also upregulates longevity genes (**FOXO, SIRT1**) and reduces oxidative damage via hormetic stress responses. Lifespan extension has been demonstrated in various preclinical models, particularly under conditions of metabolic or oxidative stress.

4. Immunomodulation and Inflammation Reduction

MOTS-c modulates immune homeostasis by suppressing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and activating anti-inflammatory signaling via AMPK and SIRT1. It has been shown to reduce systemic inflammation and mitigate autoimmune and cytokine-induced damage. This makes it promising for conditions such as rheumatoid arthritis, lupus, and neuroinflammatory diseases.

5. Neuroprotection and Cognitive Function

Emerging evidence supports MOTS-c as a neuroprotective agent. It crosses the blood-brain barrier and activates AMPK and NRF2 pathways in the brain, reducing neuroinflammation and oxidative damage. MOTS-c supports synaptic plasticity and memory consolidation and may have applications in Alzheimer's disease, Parkinson's, and age-related cognitive decline.

6. Cardiovascular and Endothelial Function

MOTS-c improves vascular tone and endothelial function by promoting nitric oxide synthesis and reducing reactive oxygen species. It has been shown to attenuate hypertrophy, reduce fibrosis, and improve ejection fraction in cardiac injury models. Its cardiovascular benefits extend to atherosclerosis prevention and blood pressure regulation.

Safety and Side Effects

Excellent Safety Profile in Preclinical and Human Studies

MOTS-c has demonstrated a robust safety profile in both animal and early-phase human studies. There are no significant adverse events reported with short- or medium-term administration in preclinical models, even at supraphysiologic doses. Rodents administered MOTS-c showed no evidence of organ toxicity, changes in blood parameters, or histopathological damage in liver, kidney, or brain tissue.

Lack of Immunogenicity and Tumorigenicity

Unlike certain peptide-based therapies, MOTS-c is naturally encoded in the mitochondrial genome and recognized as an endogenous peptide, reducing the risk of immunogenicity. Furthermore, unlike growth-promoting agents such as IGF-1, MOTS-c does not promote neoplastic activity or increase mitogenic signals. Studies have shown it does not elevate VEGF, c-Myc, or mTOR, which are often implicated in tumorigenesis.

Human Safety Experience

In early human studies evaluating metabolic and athletic performance parameters, MOTS-c has shown no clinically significant side effects. Mild and transient side effects reported anecdotally include fatigue, flushing, or injection site discomfort. No alterations in blood pressure, cardiac rhythm, or electrolyte imbalances have been documented. Its safety profile in elderly individuals and those with pre-existing conditions is still under investigation, though current data are favorable.

No Reported Drug Interactions

To date, MOTS-c has not shown pharmacokinetic or pharmacodynamic interactions with common medications, including insulin, metformin, or statins. This makes it a potential adjunct therapy in polypharmacy contexts like metabolic syndrome, diabetes, and cardiovascular disease.

Clinical Monitoring and Dosing Considerations

Dosing Strategy and Route of Administration

MOTS-c is typically administered via subcutaneous injection, reflecting its natural mitochondrial peptide structure and poor oral bioavailability. In preclinical studies, doses range from 0.5 mg/kg to 15 mg/kg, with optimal efficacy in the [redacted] range depending on the condition. Human dosing is still under clinical exploration, but anecdotal therapeutic use in the longevity and performance medicine space often utilizes doses between [redacted] **per dose**, given [redacted]. Dosing frequency is adjusted based on therapeutic goals—e.g., metabolic optimization, fatigue reduction, cognitive enhancement, or recovery acceleration.

Therapeutic Monitoring Recommendations

Given MOTS-c's pivotal influence on mitochondrial energetics, metabolic regulation, and cellular stress responses, therapeutic monitoring should be tailored to the intended clinical application. In metabolic health interventions, practitioners are advised to assess fasting glucose and HbA1c levels to track glycemic control. A comprehensive lipid panel—including total cholesterol, LDL, HDL, and triglycerides—offers insight into cardiovascular risk modulation. Optional measurements such as C-peptide and insulin levels may provide further clarity on insulin sensitivity. Body composition analysis, whether via DEXA or bioelectrical impedance analysis (BIA), can help monitor changes in lean mass, fat distribution, and metabolic efficiency.

For those employing MOTS-c to enhance physical performance or longevity, functional assessments such as VO_2 max or the 6-Minute Walk Test (6MWT) are useful for establishing baseline endurance and detecting performance improvements. Muscle strength and endurance evaluations, alongside resting heart rate and heart rate variability (HRV), serve as practical tools to gauge recovery, autonomic balance, and mitochondrial fitness. For athletes or high-performance individuals, lactate threshold testing may also be warranted.

When MOTS-c is used in neurocognitive or neuroprotective applications, practitioners may consider administering cognitive battery tests such as the Montreal Cognitive Assessment (MoCA), Trail Making Test, or Stroop test. Fatigue levels can be quantified using validated scales such as the FACIT-Fatigue Scale (FACIT-F) or the Multidimensional Fatigue Inventory (MFI). Subjective assessments of vitality, motivation, and mental clarity also provide important context for therapeutic effectiveness and patient-reported outcomes.

Longitudinal Tracking in Clinical Research or Precision Medicine

Given that MOTS-c's benefits often emerge over several weeks of use, serial tracking over 1–3 months is recommended. Tools like the RAND-36, mitochondrial function panels (e.g., lactate/pyruvate ratios, ATP assays), or transcriptomic biomarkers may be useful in investigational or advanced clinics.

Laboratory Monitoring for Adverse Events (if indicated):
Although MOTS-c has shown a very favorable safety profile, practitioners may opt to monitor:

- Basic metabolic panel (electrolytes, BUN, creatinine)
- Liver function tests
- Complete blood count (for subtle inflammatory shifts)

Clinical Summary

MOTS-c represents a new frontier in mitochondrial-based therapeutics with promising applications across metabolic, neurocognitive, cardiovascular, and immunologic domains. As a naturally occurring mitochondrial-encoded peptide, MOTS-c acts as a central regulator of cellular adaptation to stress by translocating to the nucleus and altering the expression of genes associated with metabolism, redox balance, and longevity pathways.

Its profound ability to activate AMPK, increase glucose utilization, and suppress inflammation positions MOTS-c as a therapeutic candidate for a wide array of age-related and stress-related conditions—from type 2 diabetes and sarcopenia to neuroinflammation and fatigue syndromes. Unlike synthetic pharmacological agents that target one pathway, MOTS-c operates as a systemic modulator of mitochondrial function and nuclear gene expression, allowing for broad physiologic benefits with minimal side effects.

In clinical and preclinical trials, MOTS-c has been shown to:

- Enhance insulin sensitivity and glucose tolerance
- Improve endurance and physical performance
- Reduce inflammatory markers in obesity and autoimmunity
- Mitigate cognitive fatigue and mitochondrial dysfunction
- Extend lifespan in murine models via metabolic and proteostatic enhancement

Given its excellent tolerability and emerging human data, MOTS-c offers clinicians a safe, targeted, and evolutionarily conserved tool for addressing complex, multisystem dysfunction. As ongoing research continues to explore its applications in longevity, immune resilience, cancer prevention, and cognitive performance, MOTS-c is poised to become **a foundational peptide in the clinical toolkit of functional and regenerative medicine**.

References

1. Lee, C., Zeng, J., Drew, B. G., Sallam, T., Martin-Montalvo, A., Wan, J., ... & Cohen, P. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. *Cell Metabolism*, 21(3), 443–454. https://doi.org/10.1016/j.cmet.2015.02.009

2. Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., Joly, J. H., Mitchell, C. J., Cameron-Smith, D., ... & Cohen, P. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. *Nature Communications*, 12(1), 1–14. https://doi.org/10.1038/s41467-021-24711-8

3. Lu, H., Zhang, J., Liu, D., Tang, Q., Dai, X., & Cui, D. (2020). MOTS-c peptide increases insulin sensitivity and decreases insulin resistance in skeletal muscle of type 2 diabetic rats. *Diabetes Research and Clinical Practice*, 170, 108496. https://doi.org/10.1016/j.diabres.2020.108496

4. Kim, K. H., Son, J. M., Benayoun, B. A., & Lee, C. (2019). The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. *Cell Metabolism*, 30(5), 898–909.e5. https://doi.org/10.1016/j.cmet.2019.07.008

5. Jiao, Y., Li, Y., Huang, J., Li, S., & Wang, J. (2023). MOTS-c alleviates inflammation and oxidative stress in diabetic nephropathy via AMPK/NF-κB signaling pathway. *International Immunopharmacology*, 117, 109983. https://doi.org/10.1016/j.intimp.2023.109983

6. Zeng, J., Cohen, P., & Lee, C. (2020). MOTS-c: A mitochondrial-derived peptide that regulates energy homeostasis. *Current Opinion in Pharmacology*, 52, 20–24. https://doi.org/10.1016/j.coph.2020.05.003

7. Lu, N., Wang, R., Chen, Y., Wang, Y., & Yang, Y. (2022). MOTS-c enhances cognitive function and reduces neuroinflammation in aged mice. *Frontiers in Aging Neuroscience*, 14, 869254. https://doi.org/10.3389/fnagi.2022.869254

8. Ramanjaneya, M., Jerobin, J., Bettahi, I., Sivasubramaniyam, T., Al Khayal, F., Al-Rawashdeh, K., ... & Tripathi, G. (2021). Mitochondrial-derived peptide MOTS-c: A player in aging and age-related diseases. *Cells*, 10(11), 2961. https://doi.org/10.3390/cells10112961

9. Jang, H. Y., Jang, H. J., Kim, H. J., Lee, H., & Lee, Y. (2023). MOTS-c improves endothelial dysfunction in high-fat-diet-induced obese mice through mitochondrial and nitric oxide pathways. *Biomedicine & Pharmacotherapy*, 160, 114385. https://doi.org/10.1016/j.biopha.2023.114385

10. Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016). Metformin as a tool to target aging. *Cell Metabolism*, 23(6), 1060–1065. [Includes discussion on mitochondrial peptides like MOTS-c]. https://doi.org/10.1016/j.cmet.2016.05.011